PK/PD Model-informed Dose Selection for Oncology Phase I Expansion: Case Study Based on PF-06939999, a PRMT5 Inhibitor
Overview
Affiliations
The optimal dose for targeted oncology therapeutics is often not the maximum tolerated dose. Pharmacokinetic/pharmacodynamic (PK/PD) modeling can be an effective tool to integrate clinical data to help identify the optimal dose. This case study shows the utility of population PK/PD modeling in selecting the recommended dose for expansion (RDE) for the first-in-patient (FIP) study of PF-06939999, a small-molecule inhibitor of protein arginine methyltransferase 5. In the dose escalation part of the FIP trial (NCT03854227), 28 patients with solid tumors were administered PF-06939999 at 0.5 mg, 4 mg, 6 mg, or 8 mg once daily (q.d.) or 0.5 mg, 1 mg, 2 mg, 4 mg, or 6 mg twice daily (b.i.d.). Tolerability, safety, PK, PD biomarkers (plasma symmetrical dimethyl-arginine [SDMA]), and antitumor response were assessed. Semimechanistic population PK/PD modeling analyses were performed to characterize the time-courses of plasma PF-06939999 concentrations, plasma SDMA, and platelet counts collected from 28 patients. Platelet counts were evaluated because thrombocytopenia was the treatment-related adverse event with clinical safety concern. The models adequately described the PK, SDMA, and platelet count profiles both at individual and population levels. Simulations suggested that among a range of dose levels, 6 mg q.d. would yield the optimal balance between achieving the PD target (i.e., 78% reduction in plasma SDMA) and staying below an acceptable probability of developing grade ≥3 thrombocytopenia. As a result, 6 mg q.d. was selected as the RDE. The model-informed drug development approach informed the rational dose selection for the early clinical development of PF-06939999.
Targeting RNA splicing modulation: new perspectives for anticancer strategy?.
Lv X, Sun X, Gao Y, Song X, Hu X, Gong L J Exp Clin Cancer Res. 2025; 44(1):32.
PMID: 39885614 PMC: 11781073. DOI: 10.1186/s13046-025-03279-w.
Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S Signal Transduct Target Ther. 2024; 9(1):332.
PMID: 39592582 PMC: 11627502. DOI: 10.1038/s41392-024-02039-0.
Keller S, Kunz U, Schmid U, Beusmans J, Buchert M, He M J Transl Med. 2024; 22(1):934.
PMID: 39402675 PMC: 11476076. DOI: 10.1186/s12967-024-05612-x.
Watts J, Minden M, Bachiashvili K, Brunner A, Abedin S, Crossman T Ther Adv Hematol. 2024; 15:20406207241275376.
PMID: 39290981 PMC: 11406655. DOI: 10.1177/20406207241275376.
Jayachandran P, Desikan R, Krishnaswami S, Hennig S CPT Pharmacometrics Syst Pharmacol. 2023; 12(11):1569-1572.
PMID: 37849052 PMC: 10681474. DOI: 10.1002/psp4.13066.